
[EPISODE 25] Adam Stasio Talks, Large Data Sets, Breaking Down Problems, and Tech-Driven Solutions
On this episode of Molecular Moments, Jim McNally, Ph.D., speaks with Adam Stasio, president of SciMed, whose mission is to
(Automated Immunoassays)
(MSD-Multiplex ECLIA)
(SPR Biomarker Interactions)
(ImmunoCAP)
(Western Blot Imager)
(Immune Cell Cytokine Release)
(Low Volume Automated ELISA)
(Multiplex Immunoassay)
SAN DIEGO LAB
~34,000 sq. ft.
CRO
Immunoassay
Mass Spectrometry
USA HQ (DURHAM)
~265,000 sq. ft.
Discovery
Preclinical/clinal
Manufacturing
BOSTON LAB
~22,000 sq. ft.
Bioanalytical Services
Diagnostic Testing
EUROPEAN HQ (HAMBURG)
~2,900 m2 (31,000 sq. ft.)
Assay Development
Validation
Sample Analysis
Global Disease Studies
MELBOURNE LAB
2,777 Square Meters
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Virology
Immunology
FIH trials & early-phase clinical trials
Central laboratory services
BRISBANE LAB
1,566 Square Meters
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Virology
Immunology
FIH trials & early-phase clinical trials
Central laboratory services
Explore the capabilities of each platform in more detail to learn which option will be best for your unique study. Our team is available for specific guidance on platform selection.
On this episode of Molecular Moments, Jim McNally, Ph.D., speaks with Adam Stasio, president of SciMed, whose mission is to
The third and final blog in our cell and gene therapy series will focus on PCR as a bioanalytical tool
In this article, Chief Scientific Officer at BioAgilytix, Jim McNally, Ph.D., explores why bioanalysts should prepare for the impending wave
Once the patent on a previously ground-breaking blockbuster molecule comes to an end, there is an opportunity for biosimilar versions
A3P Biomedical AB, a Swedish company specialized in advanced prostate cancer diagnostics, and BioAgilytix, a global bioanalytical services provider, have
BioAgilytix Commits to United Nations Global Compact  Leading bioanalytical services provider pledges to act in support of human rights
The third and final blog in our cell and gene therapy series will focus on PCR as a bioanalytical tool
An Overview of Cell Therapy: As we continue our blog series on cell and gene therapy, we will now dive
An Introduction to Gene Therapy: As early as the 1970’s, the term “gene therapy” was used for the treatment of
(Automated Immunoassays)
(MSD-Multiplex ECLIA)
(SPR Biomarker Interactions)
(ImmunoCAP)
(Western Blot Imager)
(Immune Cell Cytokine Release)
(Low Volume Automated ELISA)
(Multiplex Immunoassay)
SAN DIEGO LAB
~34,000 sq. ft.
CRO
Immunoassay
Mass Spectrometry
USA HQ (DURHAM)
~265,000 sq. ft.
Discovery
Preclinical/clinal
Manufacturing
BOSTON LAB
~22,000 sq. ft.
Bioanalytical Services
Diagnostic Testing
EUROPEAN HQ (HAMBURG)
~2,900 m2 (31,000 sq. ft.)
Assay Development
Validation
Sample Analysis
Global Disease Studies
MELBOURNE LAB
2,777 Square Meters
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Virology
Immunology
FIH trials & early-phase clinical trials
Central laboratory services
BRISBANE LAB
1,566 Square Meters
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Virology
Immunology
FIH trials & early-phase clinical trials
Central laboratory services
Explore the capabilities of each platform in more detail to learn which option will be best for your unique study. Our team is available for specific guidance on platform selection.
On this episode of Molecular Moments, Jim McNally, Ph.D., speaks with Adam Stasio, president of SciMed, whose mission is to
The third and final blog in our cell and gene therapy series will focus on PCR as a bioanalytical tool
In this article, Chief Scientific Officer at BioAgilytix, Jim McNally, Ph.D., explores why bioanalysts should prepare for the impending wave
Once the patent on a previously ground-breaking blockbuster molecule comes to an end, there is an opportunity for biosimilar versions
A3P Biomedical AB, a Swedish company specialized in advanced prostate cancer diagnostics, and BioAgilytix, a global bioanalytical services provider, have
BioAgilytix Commits to United Nations Global Compact  Leading bioanalytical services provider pledges to act in support of human rights
The third and final blog in our cell and gene therapy series will focus on PCR as a bioanalytical tool
An Overview of Cell Therapy: As we continue our blog series on cell and gene therapy, we will now dive
An Introduction to Gene Therapy: As early as the 1970’s, the term “gene therapy” was used for the treatment of
The ELISA method is designed for detecting and quantifying substances such as peptides, proteins, antibodies and hormones, and is typically performed on a 96-well plate. Using ELISA, detection is completed by assessing the conjugated enzyme activity via incubation with a substrate to produce a measurable signal.
The binding and immobilization of reagents done through ELISA makes it easy to separate bound from non-bound material during the assay, and wash away non-specifically bound materials to measure specific analytes.
The ELISA technique was originally developed in the 1970s, when it was created as a replacement for traditional radioimmunoassay methods. More recently however, the ELISA method has been paired with laboratory automation techniques to dramatically improve throughput and sensitivity. Such advancements include automated plate washing and automated readouts.
Learn why ELISA is still the most used immunoassay platform for supporting large molecule bioanalysis in this featured blog from a platform expert.
The ELISA method is one of the most diverse available, with applications throughout health care and small and large molecule laboratory science. The platform comes in a variety of mechanisms, including direct, indirect, sandwich, competitive and ELISpot, each with its own optimal applications.
As a bioanalytical laboratory that harnesses a variety of platforms, BioAgilytix most frequently leverages ELISA in our work with biomarkers, immunogenicity, pharmacokinetics(PK), and cell-based assays. ELISA can be leveraged in a multitude of research areas, including oncology, cardiovascular, neuroscience, and gene and cell therapies. Specifically, ELISA can be used to evaluate antibodies to specific HLA haplotype expressed by allogenous cell therapy, and supports assessment of immunogenicity, both humoral and cellular response, to the transgene, vector, and lipid nanoparticle used in cell and gene therapies.